Institution

Rigshospitalet

Copenhagen, DenmarkWebsite

513running trials
236closed trials
78,753publications (OpenAlex)

Running trials

Not yet recruiting
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
NCT07291102· Phase 3· Nationwide Children's Hospital· Source
Not yet recruiting
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408· Phase 3· Bristol-Myers Squibb· Source
Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Not yet recruiting
Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI
NCT07861217· Phase 2· Copenhagen University Hospital, Rigshospitalet· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Not yet recruiting
Dose-Escalated Short-Course Proton Therapy for Locally Advanced Rectal Cancer
NCT07903883· University of Aarhus· Source
Not yet recruiting
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
2025-522019-40-00· Phase 1/2· Novartis Pharma AG· Source
Recruiting
FLuorescent Assisted Surgery for Head and neck cancer: Perioperative Optical Imaging in Neck dissection and Transoral robotic surgery (FLASHPOINT)
2025-522845-23-00· Phase 2· Rigshospitalet· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
NCT07323316· Ad scientiam· Source
Not yet recruiting
PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors
NCT07590726· Copenhagen University Hospital, Rigshospitalet· Source
Recruiting
A dosimetry trial of uPAR targeted radioligand therapy in patients with glioblastoma
2024-520105-39-00· Phase 1· Curasight A/S· Source
Not yet recruiting
Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
NCT07825233· Centre Hospitalier Universitaire Vaudois· Source
Recruiting
A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
2025-523665-24-00· Phase 1· Novartis Pharma AG· Source
Not yet recruiting
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
NCT07870681· Phase 2/3· Oslo University Hospital· Source
Not yet recruiting
bNAbs and Anti-PD-1 in HIV
NCT07820813· Phase 2· Ole Schmeltz Søgaard· Source
Recruiting
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
NCT07476729· Phase 3· Charite University, Berlin, Germany· Source
Not yet recruiting
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· Phase 3· F. Hoffmann-La Roche AG· Source
Enrolling by invitation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
NCT07886489· University of Aarhus· Source
Recruiting
Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer
NCT07432802· Aarhus University Hospital· Source
Recruiting
A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07771465· Phase 3· Kardigan, Inc.· Source
Recruiting
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
NCT07737743· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
NCT07753993· Phase 3· AstraZeneca· Source
Not yet recruiting
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
2025-524439-38-00· Phase 2· Oslo Universitetssykehus HF· Source
Not yet recruiting
RECAP-D
2026-526685-25-00· Phase 2· Region Hovedstaden· Source
Recruiting
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· Phase 3· Institut Gustave Roussy· Source
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Not yet recruiting
The HYCORE1 Trial: Hybrid Revascularization Versus Coronary Artery Bypass Grafting
NCT05504031· Copenhagen University Hospital, Rigshospitalet· Source
Recruiting
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00· Phase 1· Janssen Cilag International· Source
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.
NCT07672236· Phase 3· OncoZenge AB· Source
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
NCT07630974· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510· Phase 3· Dianthus Therapeutics· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)
2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source
Recruiting
Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)
2024-516896-34-00· Phase 1/2· Universitaetsklinikum Heidelberg AöR· Source
Active, not recruiting
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
NCT07468071· Phase 1/2· Novartis Pharmaceuticals· Source
Not yet recruiting
A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer
NCT07455422· University Hospital, Antwerp· Source
Not yet recruiting
UNPRESCRIB-D
2026-526314-90-00· Phase 4· Region Hovedstaden· Source
Not yet recruiting
The MAYA2 trial
2025-521941-25-00· Phase 2· Odense University Hospital· Source
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328· Phase 1· Eli Lilly and Company· Source
Recruiting
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· Phase 3· Janssen Cilag International· Source
Recruiting
Vascular Complications After Kidney Transplantation
NCT07531966· University of Aarhus· Source
Recruiting
A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors
2025-521702-18-00· Phase 1· Novartis Pharma AG· Source
Recruiting
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
NCT07570173· Phase 2/3· Merck Sharp & Dohme LLC· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A
NCT07416526· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
NCT07416604· Phase 3· Hoffmann-La Roche· Source
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332· Phase 3· Inhibikase Therapeutics· Source
Recruiting
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
NCT07635368· Copenhagen University Hospital, Rigshospitalet· Source

Showing 50 of 513.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Childhood cancers63 recruiting
Lung cancer20 recruiting
Colorectal cancer16 recruiting
Heart failure16 recruiting
Acute myeloid leukaemia15 recruiting
Acute lymphoblastic leukaemia13 recruiting
Atrial fibrillation12 recruiting
Coronary artery disease12 recruiting
Stroke12 recruiting
Myelodysplastic syndromes9 recruiting
Ovarian cancer9 recruiting
Prostate cancer9 recruiting
Sarcoma9 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)8 recruiting
Chronic kidney disease7 recruiting
Bladder cancer6 recruiting
Chronic lymphocytic leukaemia6 recruiting
Head and neck cancer6 recruiting
High blood pressure6 recruiting
Hodgkin lymphoma6 recruiting
Metastatic breast cancer6 recruiting
Neuroblastoma6 recruiting
Obesity6 recruiting
Type 2 diabetes6 recruiting
Melanoma5 recruiting
Pancreatic cancer5 recruiting
Amyloidosis4 recruiting
Aortic stenosis4 recruiting
Chronic myeloid leukaemia4 recruiting
Crohn's disease4 recruiting
Endometrial cancer4 recruiting
Follicular lymphoma4 recruiting
Haemophilia4 recruiting
Mantle cell lymphoma4 recruiting
Multiple myeloma4 recruiting
Myasthenia gravis4 recruiting
Type 1 diabetes4 recruiting
Aortic aneurysm3 recruiting
Cystic fibrosis3 recruiting
Dilated cardiomyopathy3 recruiting
Gastric and oesophageal cancer3 recruiting
Glioblastoma3 recruiting
HIV3 recruiting
Lupus (SLE)3 recruiting
ANCA-associated vasculitis2 recruiting
Barrett's oesophagus2 recruiting
Cerebral palsy2 recruiting
Cervical cancer2 recruiting
Depression2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Fabry disease2 recruiting
Hepatitis B2 recruiting
Huntington's disease2 recruiting
Idiopathic pulmonary fibrosis2 recruiting
Liver and biliary tract cancer2 recruiting
Macular degeneration2 recruiting
Multiple sclerosis2 recruiting
Neuroendocrine tumours2 recruiting
Osteoarthritis2 recruiting
Pulmonary arterial hypertension2 recruiting
Rheumatoid arthritis2 recruiting
Sjögren's disease2 recruiting
Thalassaemia2 recruiting
Ventricular tachycardia2 recruiting
Alzheimer disease1 recruiting
Autism1 recruiting
Brain aneurysm1 recruiting
Bronchiectasis1 recruiting
Congenital heart disease1 recruiting
COPD1 recruiting
Cytomegalovirus infection1 recruiting
Dermatomyositis and polymyositis (myositis)1 recruiting
Duchenne muscular dystrophy1 recruiting
Epilepsy1 recruiting
Glaucoma1 recruiting
Hearing loss1 recruiting
Hepatitis C1 recruiting
Hydrocephalus1 recruiting
Hypertrophic cardiomyopathy1 recruiting
Lyme disease1 recruiting
Meningioma1 recruiting
Osteoporosis1 recruiting
Pompe disease1 recruiting
Postural tachycardia syndrome (POTS)1 recruiting
Sarcoidosis1 recruiting
Sickle cell disease1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Thyroid cancer1 recruiting
Trigeminal neuralgia1 recruiting
Triple-negative breast cancer1 recruiting
Ulcerative colitis1 recruiting

Closed trials

Recruiting
ROSY-F: Roll-over Study for Participants Who Have Completed a Previous Clinical Study with Benralizumab (Fasenra) and Benefit from Continued Treatment
2025-523307-29-00· Phase 3· AstraZeneca AB· Source
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264· Phase 3· CSL Behring· Source
Not yet recruiting
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
2024-515627-10-00· Phase 1/2· Bonsai Biotherapeutics AB· Source
Completed
ARIISE - ASCs in recently diagnosed non-ischemic heart failure
NCT06840275· Phase 2· Cell2Cure ApS· Source
Active, not recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
NCT07246941· Phase 1· Hoffmann-La Roche· Source
Completed
Steroids and/ or Non-steroidal Anti-inflammatory Drugs in the Postoperative Regime After Trabeculectomy. (SNAP)
NCT04054830· Phase 4· Rigshospitalet· Source
Active, not recruiting
Study of zoldonrasib in Previously Treated Patients with RAS G12D-Mutant Non-Small Cell Lung Cancer (NSCLC)
2025-521681-10-00· Phase 2· Revolution Medicines Inc.· Source
Recruiting
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
2024-520050-38-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Completed
A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP
2024-518364-12-00· Phase 2· Immunovant Sciences GmbH· Source
Completed
A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status
2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source
Active, not recruiting
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT06521567· Phase 1/2· GlaxoSmithKline· Source
Completed
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors
NCT06232408· Phase 1· Repare Therapeutics USA Inc.· Source
Active, not recruiting
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
NCT06667687· Phase 1· AbbVie· Source
Recruiting
Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
NCT06613009· Phase 1· Innovent Biologics (Suzhou) Co. Ltd.· Source
Completed
ARETHA: cARdiomems vEriciguaT Heart fAilure (A double-blind randomized placebo-controlled trial of vericiguat in heart failure patients with CardioMEMS™ HF System)
2024-514111-10-00· Phase 4· Rigshospitalet· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155· Phase 2· argenx· Source
Completed
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source
Active, not recruiting
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
NCT06413706· Phase 2· Eli Lilly and Company· Source
Recruiting
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis
2023-504358-36-00· Phase 3· Sanofi-Aventis Recherche & Developpement· Source
Completed
Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour
NCT06796335· Copenhagen University Hospital, Rigshospitalet· Source
Completed
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
NCT06482437· Phase 2· NMD Pharma A/S· Source
Completed
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
NCT06254495· Phase 1· Seagen Inc.· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801· Phase 3· Gossamer Bio USA, Inc.· Source
Completed
A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)
2023-506240-16-00· Phase 1/2· Sutro Biopharma Inc.· Source
Completed
Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease
2023-507892-23-00· Phase 2· NMD Pharma A/S· Source
Completed
Mobilization Before and After Video-Assisted Thoracoscopic Surgery Lobectomy/Segmentectomy
NCT07338474· Copenhagen University Hospital, Rigshospitalet· Source
Active, not recruiting
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941· Phase 2· Novartis Pharmaceuticals· Source
Completed
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
NCT06435273· Phase 2· AstraZeneca· Source
Active, not recruiting
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580· Phase 3· Vor Biopharma· Source
Active, not recruiting
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
NCT06483334· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
NCT06465303· Phase 2· ResoTher Pharma· Source
Completed
Pulmonary Diffusing Capacity During Incremental Exercise in COPD
NCT06505902· Copenhagen University Hospital, Rigshospitalet· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Completed
Open-label Extension of Vericiguat in Pediatric Participants with Heart Failure due to Left Ventricular Systolic Dysfunction
2023-506210-40-00· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )
NCT06341712· Phase 2· Ipsen Innovation· Source
Completed
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
NCT06120504· Phase 1· Seagen Inc.· Source
Completed
Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)
NCT06287476· Copenhagen University Hospital, Rigshospitalet· Source
Completed
Strength Training Exercises to Minimise Late Effects of Childhood Leukaemia or Lymphoma Among Adolescents
NCT06299722· Aalborg University· Source
Completed
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
NCT06323928· Phase 2· H. Lundbeck A/S· Source
Completed
Feasibility and Safety of Home Blood Count Measurement and Transfusions in Patients With Acute Myeloid Leukemia
NCT07062250· Copenhagen University Hospital, Rigshospitalet· Source
Active, not recruiting
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
A Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
2022-502457-34-00· Phase 2· F. Hoffmann-La Roche AG· Source
Completed
A Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients with SBMA
2023-507128-22-00· Phase 2· Nido Biosciences Inc.· Source
Completed
GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer
2022-502453-33-00· Phase 2· Genmab A/S· Source
Recruiting
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
NCT06035120· Pulmonx Corporation· Source
Recruiting
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423· Phase 1· OnCusp Therapeutics, Inc.· Source
Completed
EMPagliflozin after Aortic Valve Replacement - the EMPAVR study
2023-504731-40-01· Phase 4· Rigshospitalet· Source
Completed
Maximal Oxygen Uptake (VO2max) in Patients With COPD
NCT06257381· Copenhagen University Hospital, Rigshospitalet· Source

Showing 50 of 236.

Registry name variants (97)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Rigshospitalet
Copenhagen Oe, 2100
410 trials
Rigshospitalet
Copenhagen, Ø 2100
189 trials
Rigshospitalet
Glostrup, 2600
42 trials
Rigshospitalet
København Ø, 2100
19 trials
Rigshospitalet, Copenhagen
Copenhagen, Copenhagen DK-2100
13 trials
Department of Cardiology and Radiology, Rigshospitalet, The Heart Center, Capital Region of Copenhagen, University of Copenhagen
Copenhagen, 2100
5 trials
Center for Aktiv Sundhed (CFAS), Rigshospitalet, Copenhagen, Denmark.
Copenhagen, København Ø 2100
3 trials
- NCT06505902Pulmonary Diffusing Capacity During Incremental Exercise in COPD
- NCT06257381Maximal Oxygen Uptake (VO2max) in Patients With COPD
- NCT06135701Femoral Artery Blood Flow During Rest and One-leg Knee Extensor Exercise in Patients With COPD
Department of Cardiology, Rigshospitalet
Copenhagen, 2100
3 trials
- NCT06653725Exogenous KETOne Supplements in Patients Hospitalized for Acute Heart Failure
  Contact: Jacob Eifer Møller, MD, PhD, DMSc
- NCT06560047Danish Evaluation of Early Catheter Ablation for Atrial Fibrillation in Patients With Heart Failure
  Contact: Anne-Christine Ruwald, MD, PhD
- NCT06661434Prevalence of Obesity Among Adult Patients With Congenital Heart Disease: a Population-based Study
Center for Cancer and Organ Diseases - Rigshospitalet
Copenhagen, 2100
2 trials
- NCT07101328A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- NCT05786924Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
  Contact: Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Department of Growth and Reproduction, Rigshospitalet
Copenhagen, 2100
2 trials
- NCT07316387Neurobehavioral Development in Toddlers and Preschoolers in Relation to Prenatal Exposure of Mild Analgesics (NeuroToP - a COPANA Follow up)
- NCT04848545Endocrine Disrupting Chemical Exposure and Testicular Cancer
Department of Nephrology, Rigshospitalet
Copenhagen, Ø 2100
2 trials
- NCT05730257Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation
- NCT04841304Cardiac Arrhythmia in Patients With End-Stage Renal Disease
Department of Pediatrics and Adolescent Medicine and Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, Copenhagen Ø 2100
2 trials
- NCT06486597Whole Body Metabolism in Children With Cerebral Palsy With Low Skeletal Muscle Mass
  Contact: Mette Cathrine Ørngreen, MD, DMSc
- NCT06380387Whole Body Metabolism in Children Before and After Treatment of CNS Tumor
  Contact: Mette Cathrine Ørngreen, MD, DMSc
Heart Center, Rigshospitalet
Copenhagen, Capital Region 2100
2 trials
- NCT05462730Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction
- NCT04775914STEMI Treatment Optimization by Ischemic Postconditioning and IVUS Guidance
  Contact: Thomas Engstrom, MD PhD DSci
Rigshospitalet (CFAS)
Copenhagen, 2100
2 trials
- NCT06211556Depletion of Liver Fat in Type 2 Diabetes
  Contact: Inge Holm
- NCT05579340Postoperative Exercise Training and Colorectal Cancer Liver Metastasis
Rigshospitalet, Department of Otorhinolaryngology, Head & Neck Surgery & Audiology
Copenhagen, 2100
2 trials
- NCT05841966Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
- NCT05696314Surgeon-performed Outpatient Transoral and Transcervical Ultrasound of the Oropharynx
The Heart Center, Rigshospitalet
Copenhagen, Dr. 2100
2 trials
- NCT07354347Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD
  Contact: Bo G Winkel, MD, PhD
- NCT07405229MEdical Treatment in Idiopathic Ventricular Fibrillation Patients
  Contact: Bo G Winkel, MD, PhD
Center For Physical Activity Research, Rigshospitalet
Copenhagen
1 trial
- NCT06287476Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)
Center for Pregnant Women with Diabetes, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT07240012Automated Insulin Delivery Versus Usual Insulin Treatment Modality Before and During Pregnancy in Women With Type 1 Diabetes
  Contact: Lene Ringholm Chief physician, PhD, Associate Professor
Copenhagen Center for Arthritis Research (COPECARE), Rigshospitalet
Copenhagen
1 trial
- NCT07825233Pix-Risk: Early Detection of Rheumatoid Arthritis Via the DETECTRA Platform
  Contact: Lene Terslev
Copenhagen Neuromuscular Center, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06040567Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Department for Cardiothoracic Surgery, Rigshospitalet
Copenhagen, Copenhagen 2100
1 trial
- NCT07338474Mobilization Before and After Video-Assisted Thoracoscopic Surgery Lobectomy/Segmentectomy
Department of cardiothoracic surgery, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT05709470Mind the Heart - Mental Health in Children and Adolescents With Congenital Heart Defects
  Contact: Sara H Lau-Jensen, MD
Department of Clinical Oncology, Rigshospitalet
Copenhagen, Danmark 2100
1 trial
- NCT03315546Radiotherapy Delivery in Deep Inspiration for Pediatric Patients
  Contact: Maja V Maraldo
Department of Endocrinology, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT07250789Cognitive Screening and Multidomain Intervention Targeting Cognitive Decline in Type 2 Diabetes (The Brain Care Study)
  Contact: Malin S. D. Nilsson, MD, PhD
Department of Infectious Diseases, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT03418441Central Nervous System Infections in Denmark
  Contact: Jannik Helweg-Larsen, MD
Department of Medical Endocrinology, Rigshospitalet
Copenhagen
1 trial
- NCT01611896Selenium Supplementation Versus Placebo in Patients With Graves' Hyperthyroidism
Department of neurosurgery, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06796335Development and Implementation of an Intervention Enhancing Involvement of Relatives to Patients With Acquired Brain Injury or Malignant Brain Tumour
Department of Obstetrics, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT03949829The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Department of Oncology 5073, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06480110Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
  Contact: Helle Pappot, MD, DMSc
Department of Oncology, Rigshospitalet
Copenhagen
1 trial
- NCT02438839Curative Chemoradiation of Low Rectal Cancer
Department of Otorhinolaryngology Head and Neck Surgery and Audiology, Rigshospitalet
Copenhagen
1 trial
- NCT07203911Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Contact: Tobias Todsen, MD, PhD, Ass. Prof.
Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet
Copenhagen, Copenhagen 2100
1 trial
- NCT05707078PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
  Contact: Jacob H Rasmussen, MD, PhD, Ass. Professor
Department of Paediatrics and Adolescent Medicine, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT07635368Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
  Contact: Kia Hee Schultz Dungu, MD
Department of Urology, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06709196Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
  Contact: Andreas Røder, Prof, MD, PhD
Dept. of Nephrology, Rigshospitalet
Copenhagen, Copenhagen 2100
1 trial
- NCT04876963HOLT-ED: Holter-monitoring in End-stage Renal Disease
Dept. of Oncology, Rigshospitalet, Denmark
Copenhagen, Capital Region
1 trial
- NCT05350475Protons vs. Photons for High-risk Prostate Cancer
Dept. of Otorhinolaryngology, Head & Neck Surg, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06314711Ex Vivo 3D-ultrasound for Oropharyngeal Cancer
Hjertecenteret, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06465303A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)
Juliane Marie Center, Rigshospitalet
Copenhagen
1 trial
- NCT05076149A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
Kardiologisk Forskningsenhed 2161, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT06714123Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
  Contact: Rikke Brandt Forskningssygeplejerske
LEADR: Rigshospitalet
Copenhagen, 2100
1 trial
- NCT04863664Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
Neurobiology Research Unit, Rigshospitalet
Copenhagen, 2100
1 trial
- NCT05450822Precision Medicine in the Treatment of Epilepsy
  Contact: Gitte M Knudsen, DMSc
Rigshospitalet
Copenhagen O, Capital 2100
1 trial
- NCT05404100Effects of Aortic Valve Replacement on Myocardial T1 Values in Severe Aortic Valve Stenosis
Rigshospitalet
Glostrup Municipality, 2600
1 trial
- NCT07374705Disentangling the Effect of Brain Insulin Resistance on Brain Health
  Contact: Henrik BW Larsson, Professor
Rigshospitalet
KÃ¸benhavn, 2100
1 trial
- NCT04303780Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).
Rigshospitalet
Roenne, 3700
1 trial
- NCT04481555Eosinophil-guided Reduction of Inhaled Corticosteroids
Rigshospitalet (Blegdamsvej)
Copenhagen Ø, 2100
1 trial
- NCT05336435A Study of Population and Sex-specific Troponin Cutoffs for Ruling Out Acute Myocardial Infarction
Rigshospitalet, Copenhagen Prostate Cancer Center
Copenhagen, 2200
1 trial
- NCT04114825Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer
Rigshospitalet, Department of Clinical Biochemistry and Endocrinology
Copenhagen, 2200
1 trial
- NCT06509776Skeletal Maturation and Endocrine Health in Young Adults
Rigshospitalet, Department of Hematology
Copenhagen, 2100
1 trial
- NCT04536792A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease
Rigshospitalet, Department of Neurology
Copenhagen
1 trial
- NCT06482437Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Rigshospitalet, Department of Otorhinolaryngology, Head and Neck Surgery & Audiology
Copenhagen, 2100
1 trial
- NCT05598814Mepolizumab to CRSwNP Through 12 Months - Randomised to FESS and Non-FESS Within the First 2 Weeks
Rigshospitalet, Dept of Haematology
Copenhagen, 2100
1 trial
- NCT03911128A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
  Contact: Trial Central Office
Rigshospitalet, Dept of Paediatrics
Copenhagen, 2100
1 trial
- NCT03911128A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
  Contact: Trial Central Office
Rigshospitalet, Hjertecentret
Copenhagen, 2100
1 trial
- NCT03216733SORT OUT X - Combo Stent Versus ORSIRO Stent
Rigshospitalet /ID# 124891
Copenhagen Ø, Capital Region 2100
1 trial
- NCT02163694A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
Rigshospitalet /ID# 98238
Copenhagen Ø, Capital Region 2100
1 trial
- NCT01848561A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen
Copenhagen, 2100
1 trial
- NCT06953583A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Rigshospitalet - Kræftbehandling
Copenhagen OE, 2100
1 trial
- NCT02576431A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
Rigshospitalet, Region h, Department Oncology
Copenhagen, DK-2001
1 trial
- NCT02102477Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer
  Contact: Peter M Meidahl Petersen, M.D ass
Rigshospitalet (RH)
Copenhagen, 2100
1 trial
- NCT05963698The Fourth Left Atrial Appendage Occlusion Study
  Contact: Ole De Backer, MD (principal investigator)
Rigshospitalet (Site 0199)
Copenhagen, Capital Region 2100
1 trial
- NCT04210115Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Rigshospitalet (Site 0304)
Copenhagen, Capital Region 2100
1 trial
- NCT04924075Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
  Contact: Toll Free Number
Rigshospitalet (Site 0680)
Copenhagen, Capital Region 2100
1 trial
- NCT03898180Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
Rigshospitalet (Site 0702)
Copenhagen, Capital Region 2100
1 trial
- NCT04776148Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Rigshospitalet (Site 1180)
Copenhagen, Capital Region 2100
1 trial
- NCT06312176A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
  Contact: Study Coordinator
Rigshospitalet (Site 2102)
Copenhagen, Capital Region 2100
1 trial
- NCT04949256Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
Rigshospitalet (Site 3202)
Copenhagen, Capital Region 2100
1 trial
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
The Heart Center, Rigshospitalet, University of Copenhagen
Copenhagen, 2100
1 trial
- NCT03787745Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
  Contact: Thomas Engstrøm, DMSci
The Heart Centre, Rigshospitalet
Copenhagen, 2200
1 trial
- NCT05635227Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery
  Contact: Christian Hassager, MD, DMSc
Urological Research Unit, Rigshospitalet
Copenhagen, N 2200
1 trial
- NCT05730257Study Investigating Whether Robot-assisted Surgery Can Reduce Surgical Complications Following Kidney Transplantation
#4001, Rigshospitalet - Blegdamsvej
Copenhagen
Børneonkologisk afsnit 5054, BørneUngeKlinikken, Juliane Marie Centret, Rigshospitalet
Copenhagen, 2100 Ø
Center for Cancer and Organ Diseases - Rigshospitalet - Hornum Mads
Copenhagen
Department of Hematology, Rigshospitalet
Copenhagen, 2100
Dep. of Hematology, Rigshospitalet
Copenhagen, 2100
Medical Endocrinology PE 2132, Rigshospitalet
Copenhagen, 2100
Paediatric Stem Cell Transplant and Immune Deficiency, Dept. for children and adolescents 4072, Rigshospitalet
Copenhagen, 2100
Rigshospitalet
Copenhagen N, 2200
Rigshospitalet
Hovedstaden, 2100
Rigshospitalet - Børn og Unge
Copenhagen, 2100
Rigshospitalet, Department of Cardiology
Copenhagen
Rigshospitalet, Dept of Radiology
Copenhagen, 2100
Rigshospitalet - Glostrup
Copenhagen, 2100
Rigshospitalet /ID# 164420
Copenhagen Ø, Capital Region 2100
Rigshospitalet /ID# 224213
Copenhagen Ø, Capital Region 2100
Rigshospitalet /ID# 226576
Copenhagen Ø, Capital Region 2100
Rigshospitalet /ID# 260779
Copenhagen Ø, Capital Region 2100
Rigshospitalet - Neurologisk Afdeling
Copenhagen
Rigshospitalet (Site 0576)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 0801)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 0802)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 0903)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 0904)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 1102)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 1904)
Copenhagen, Capital Region 2100
Rigshospitalet (Site 4467)
Copenhagen, Capital Region DK-2100

Conditions

Diseases this institution publishes on or runs trials for.

Heart failure230 works · 29 trials
Stroke173 works · 23 trials
Atrial fibrillation108 works · 21 trials
Type 2 diabetes74 works · 8 trials
Migraine69 works · 10 trials
Chronic kidney disease52 works · 19 trials
Coronary artery disease47 works · 30 trials
Epilepsy46 works · 1 trial
Multiple sclerosis44 works · 15 trials
Aortic stenosis36 works · 18 trials
Rheumatoid arthritis30 works · 4 trials
Multiple myeloma29 works · 24 trials
Ovarian cancer29 works · 19 trials
Cystic fibrosis29 works · 7 trials
Acute lymphoblastic leukaemia28 works · 25 trials
COPD27 works · 8 trials
Ankylosing spondylitis26 works · 1 trial
Sarcoma24 works · 13 trials
Type 1 diabetes23 works · 5 trials
Childhood cancers22 works · 106 trials
Hodgkin lymphoma21 works · 22 trials
Lupus (SLE)21 works · 4 trials
Head and neck cancer21 works · 15 trials
Psoriatic arthritis20 works · 1 trial
Myasthenia gravis20 works · 13 trials
Osteoporosis20 works · 1 trial
Endometrial cancer19 works · 11 trials
Hearing loss19 works · 2 trials
Meningioma17 works · 1 trial
Chronic lymphocytic leukaemia16 works · 22 trials

Institution data: ROR 03mchdq19 (CC0-1.0)Updated 12 Nov 2026

Report an error